The Governance RegisterEdition 2026 · Compiled 12th July 2026

Genome Therapeutics LTD

Company 12392992 Active

Connected board network

The connection graph needs a free account.

This company's record is public. The network of who else its directors govern is compiled from the registers by us, and an account keeps it out of bulk scrapers.

Sign in, free

Board DNA

How this board is put together, from the Companies House officer record and Charity Commission trustee records - deterministic, no AI.iBoard compositionCounted from the dated Companies House officer record: the current directors only, past directors excluded.

5 directors on the board

1.8y median 0.9y
average tenure
4.2y
longest tenure
0
directors past 6 years

First-time vs portfolio directors

First-time (3)

Portfolio (2)

0
also govern a charity

Left in the last 12 months

Where else this board sits iWhere else this board sitsThe charitable fields these directors govern in elsewhere, by Charity Commission classification. Excludes this company and any charity it is the legal face of.

Professional services 5Business services 4Tech and media 3Construction 1Education 1Finance 1Property 1

The sectors these directors govern in elsewhere. This company, and any charity it is the legal face of, are excluded - counting them would just tell you what you are already looking at.

Related organisations iRelated organisationsTwo groups, both deterministic from public records. Related organisations share two or more directors with this board - a real structural link, such as a subsidiary or group company. Connected through a shared director share exactly one person - a genuine connection, but not the same group.

Connected through a shared director

Deterministic, from public records.

Company details

Number12392992
StatusActive
TypePrivate Limited Company
Incorporated08/01/2020
AddressREGENT HOUSE, 316 BEULAH HILL, LONDON, SE19 3HF
Accounts next due31/03/2027
Accounts last made up30/06/2025

Industry (SIC)

72110 - Research and experimental development on biotechnology

Ownership - persons with significant control (4)

  • Prof Sir Shankar Balasubramanian ceased 2025 British,Indian
    ownership of shares 25-50% voting rights 25-50%
  • Dr Bobby Satyadev Yerramilli-Rao ceased 2020 British
    ownership of shares 25-50% voting rights 25-50%
  • Dr Samuel Aparicio ceased 2024 Canadian
    ownership of shares 25-50% voting rights 25-50%
  • Dr Samuel Aparicio ceased 2025 Canadian
    ownership of shares 25-50% voting rights 25-50%

Officers (7)

Show 2 former officers

Directors and officers on the Companies House record, current and former.

Report an error in this record - let us know.